cardiomyopathy
-
Aiming to catch Alnylam, AstraZeneca & Ionis plan FDA filing for rare disease drug
The planned FDA submission follows the report from AstraZeneca and Ionis Pharmaceuticals that their partnered drug, eplontersen, met the main goals of a pivotal study in treating nerve pain caused by hereditary transthyretin-mediated amyloidosis. The data come one week after rival Alnylam Pharmaceuticals won FDA approval for its second drug for this rare disease.
-
FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder
An analyst wrote that the drug’s high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam’s Onpattro.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Heart disease startup MyoKardia files for IPO
Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it’s developing small molecule drugs to treat cardiomyopathies.
-
MyoKardia raises $46M Series B for precision medicine approach to cardiomyopathy
San Francisco startup MyoKardia just closed a $46 million Series B for its precision medicine approach […]
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
